cDNA microarray and bioinformatic analysis for the identification of key genes in Alzheimer's disease

Gu,Chao; Shen,Ting

doi:10.3892/ijmm.2013.1575

cDNA microarray and bioinformatic analysis for the identification of key genes in Alzheimer's disease

Authors:
- Chao Gu
- Ting Shen
View Affiliations

Affiliations: Department of Neurology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, P.R. China, Department of Emergency, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai 200071, P.R. China
Published online on: December 4, 2013 https://doi.org/10.3892/ijmm.2013.1575
Pages: 457-461

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In this study, gene expression profiles in peripheral blood monocytes from patients with Alzheimer's disease (AD) or mild cognitive impairment (MCI) were compared with those of healthy individuals to identify key differentially expressed genes (DEGs), in an effort to broaden our understanding of the pathogenesis of these diseases and identify potential therapeutic targets. The microarray data set GSE18309 was downloaded from Gene Expression Omnibus, including 3 AD, 3 MCI and 3 normal control (NC) samples. Raw data were processed and differential analysis was performed using the R multtest package. Two groups of comparisons (AD vs. NC and MCI vs. NC) were conducted and two groups of DEGs were acquired. The common DEGs were selected, for which functional enrichment analysis, as well as pathway enrichment analysis were performed to determine their roles in the development of the diseases in question. A total of 405 DEGs were identified in the AD vs. NC samples and 395 in the MCI vs. NC samples. A total of 60 common DEGs were obtained. Functional enrichment analysis revealed that the most common functions of the DEGs identified were response to nutrients, muscle contraction and cellular homeostasis. As shown by pathway enrichment analysis, the most common pathway associated with the DEGs identifed was the neuroactive ligand-receptor interaction pathway. A range of DEGs was identified in the present study, which may help to disclose the molecular mechanisms responsible for AD and may thus provide potential novel therapeutic strategies for Ad.

View Figures

View References

1	Ferri CP, Prince M, Brayne C, et al: Global prevalence of dementia: a Delphi consensus study. Lancet. 366:2112–2117. 2005. View Article : Google Scholar : PubMed/NCBI
2	Ballard C, Chalmers K, Todd C, et al: Cholinesterase inhibitors reduce cortical Aβ in dementia with Lewy bodies. Neurology. 68:1726–1729. 2007.
3	O’Brien RJ and Wong PC: Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci. 34:185–204. 2011.
4	Duff K, Eckman C, Zehr C, et al: Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 383:710–713. 1996. View Article : Google Scholar : PubMed/NCBI
5	Jayadev S, Case A, Eastman AJ, et al: Presenilin 2 is the predominant γ-secretase in microglia and modulates cytokine release. PloS One. 5:e157432010.
6	Strittmatter WJ, Saunders AM, Schmechel D, et al: Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA. 90:1977–1981. 1993. View Article : Google Scholar : PubMed/NCBI
7	Parihar M and Hemnani T: Alzheimer’s disease pathogenesis and therapeutic interventions. J Clin Neurosci. 11:456–467. 2004.
8	Pasinetti GM: Use of cDNA microarray in the search for molecular markers involved in the onset of Alzheimer’s disease dementia. J Neurosci Res. 65:471–476. 2001.PubMed/NCBI
9	Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR and Landfield PW: Incipient Alzheimer’s disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA. 101:2173–2178. 2004.
10	Maes OC, Xu S, Yu B, Chertkow HM, Wang E and Schipper HM: Transcriptional profiling of Alzheimer blood mononuclear cells by microarray. Neurobiol Aging. 28:1795–1809. 2007. View Article : Google Scholar : PubMed/NCBI
11	Troyanskaya O, Cantor M, Sherlock G, et al: Missing value estimation methods for DNA microarrays. Bioinformatics. 17:520–525. 2001. View Article : Google Scholar : PubMed/NCBI
12	Fujita A, Sato JR, de Rodrigues LO, Ferreira CE and Sogayar MC: Evaluating different methods of microarray data normalization. BMC Bioinformatics. 7:4692006. View Article : Google Scholar : PubMed/NCBI
13	Pollard KS, Dudoit S and van der Laan MJ: Multiple testing procedures: R multtest package and applications to genomics. Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Gentleman R, Carey V, Huber W, Irizarry R and Dudoit S: Springer; New York: pp. 251–272. 2005
14	Szklarczyk D, Franceschini A, Kuhn M, et al: The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acid Res. 39:D561–D568. 2011. View Article : Google Scholar : PubMed/NCBI
15	Shannon P, Markiel A, Ozier O, et al: Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
16	Berriz GF, Beaver JE, Cenik C, Tasan M and Roth FP: Next generation software for functional trend analysis. Bioinformatics. 25:3043–3044. 2009. View Article : Google Scholar : PubMed/NCBI
17	Hosack DA, Dennis G Jr, Sherman BT, Lane HC and Lempicki RA: Identifying biological themes within lists of genes with EASE. Genome Biol. 4:R702003. View Article : Google Scholar : PubMed/NCBI
18	Balk EM, Raman G, Tatsioni A, Chung M, Lau J and Rosenberg IH: Vitamin B6, B12, and folic acid supplementation and cognitive function: a systematic review of randomized trials. Arch Intern Med. 167:21–30. 2007. View Article : Google Scholar : PubMed/NCBI
19	Wyss-Coray T: Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med. 12:1005–1015. 2006.PubMed/NCBI
20	Müller M, Carter S, Hofer MJ and Campbell IL: Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity - a tale of conflict and conundrum. Neuropathol Appl Neurobiol. 36:368–387. 2010.PubMed/NCBI
21	Salminen A, Kauppinen A, Suuronen T, Kaarniranta K and Ojala J: ER stress in Alzheimer’s disease: a novel neuronal trigger for inflammation and Alzheimer’s pathology. J Neuroinflammation. 6:412009.
22	Gargalovic PS, Gharavi NM, Clark MJ, et al: The unfolded protein response is an important regulator of inflammatory genes in endothelial cells. Arterioscler Thromb Vasc Biol. 26:2490–2496. 2006. View Article : Google Scholar : PubMed/NCBI
23	Zhang K and Kaufman RJ: From endoplasmic-reticulum stress to the inflammatory response. Nature. 454:455–462. 2008. View Article : Google Scholar : PubMed/NCBI
24	Catricala S, Torti M and Ricevuti G: Alzheimer disease and platelets: how’s that relevant. Immun Ageing. 9:202012.
25	Casserly I and Topol E: Convergence of atherosclerosis and Alzheimer’s disease: inflammation, cholesterol, and misfolded proteins. Lancet. 363:1139–1146. 2004.
26	Harold D, Abraham R, Hollingworth P, et al: Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet. 41:1088–1093. 2009.
27	Lambert JC, Heath S, Even G, et al: Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet. 41:1094–1099. 2009.
28	Braskie MN, Jahanshad N, Stein JL, et al: Common Alzheimer’s disease risk variant within the CLU gene affects white matter microstructure in young adults. J Neurosci. 31:6764–6770. 2011.
29	Morris MC, Evans DA, Bienias JL, et al: Dietary intake of antioxidant nutrients and the risk of incident Alzheimer disease in a biracial community study. JAMA. 287:3230–3237. 2002. View Article : Google Scholar : PubMed/NCBI
30	Luchsinger JA and Mayeux R: Dietary factors and Alzheimer’s disease. Lancet Neurol. 3:579–587. 2004.
31	Luchsinger JA, Noble JM and Scarmeas N: Diet and Alzheimer’s disease. Curr Neurol Neurosci Rep. 7:366–372. 2007.
32	Liu J and Ames BN: Reducing mitochondrial decay with mitochondrial nutrients to delay and treat cognitive dysfunction, Alzheimer’s disease, and Parkinson’s disease. Nutr Neurosci. 8:67–89. 2005.PubMed/NCBI
33	Lefebvre T, Dehennaut V, Guinez C, et al: Dysregulation of the nutrient/stress sensor O-GlcNAcylation is involved in the etiology of cardiovascular disorders, type-2 diabetes and Alzheimer’s disease. Biochim Biophys Acta. 1800:67–79. 2010.PubMed/NCBI
34	Gordon-Weeks PR and Fischer I: MAP1B expression and microtubule stability in growing and regenerating axons. Microsc Res Tech. 48:63–74. 2000. View Article : Google Scholar : PubMed/NCBI
35	Ulloa L, Montejo de Garcini E, Gómez-Ramos P, Morán MA and Avila J: Microtubule-associated protein MAP1B showing a fetal phosphorylation pattern is present in sites of neurofibrillary degeneration in brains of Alzheimer’s disease patients. Brain Res Mol Brain Res. 26:113–122. 1994.PubMed/NCBI
36	Hasegawa M, Arai T and Ihara Y: Immunochemical evidence that fragments of phosphorylated MAP5 (MAP1B) are bound to neurofibrillary tangles in Alzheimer’s disease. Neuron. 4:909–918. 1990.PubMed/NCBI
37	García-Bueno B, Caso JR and Leza JC: Stress as a neuroinflammatory condition in brain: damaging and protective mechanisms. Neurosci Biobehav Rev. 32:1136–1151. 2008.PubMed/NCBI
38	Hampel H, Teipel SJ, Padberg F, et al: Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer’s disease. Brain Res. 823:104–112. 1999.PubMed/NCBI
39	Huppi K, Siwarski D, Pisegna J and Wank S: Chromosomal localization of the gastric and brain receptors for cholecystokinin (CCKAR and CCKBR) in human and mouse. Genomics. 25:727–729. 1995. View Article : Google Scholar : PubMed/NCBI
40	Wang J, Si YM, Liu ZL and Yu L: Cholecystokinin, cholecystokinin-A receptor and cholecystokinin-B receptor gene polymorphisms in Parkinson’s disease. Pharmacogenetics. 13:365–369. 2003.
41	Köles L, Furst S and Illes P: P2X and P2Y receptors as possible targets of therapeutic manipulations in CNS illnesses. Drug News Perspect. 18:85–101. 2005.PubMed/NCBI
42	Ryu JK and McLarnon JG: Block of purinergic P2X7 receptor is neuroprotective in an animal model of Alzheimer’s disease. Neuroreport. 19:1715–1719. 2008.PubMed/NCBI
43	da Silva RL, Resende RR and Ulrich H: Alternative splicing of P2X6 receptors in developing mouse brain and during in vitro neuronal differentiation. Exp Physiol. 92:139–145. 2007.PubMed/NCBI